Boehringer Ingelheim China

This sponsor has funded 7 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
32423 Ongoing START: Real-world study on sequential therapy with afatinib as first-line treatment in patients with epidermal growth factor receptor (EGFR)... No No
41345 Finalised Comparative safety and effectiveness of warfarin, dabigatran, and rivaroxaban among Japanese patients with non-valvular atrial fibrillation (NVAF) and... Yes Yes
41540 Planned Effectiveness and safety of IV rt-PA treatment in Chinese AIS patients aged above 80 years: a real-world study (0135-0349) No No
41543 Finalised 1-year clinical outcomes after intravenous rt-PA for Chinese AIS patients (0135-0350) No No
47368 Planned Safety profile of Tiotropium + Olodaterol used as maintenance treatment in COPD patients in Taiwan: a non-interventional study based on the Taiwan... No No
47389 Planned Effectiveness of Maintenance Treatment with Tiotropium + Olodaterol in Comparison to Inhaled Corticosteroids + Long-acting β2 agonists in COPD... No No
49529 Planned Safety of nintedanib in real world in China: a non interventional study based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study... No No

PAS by Risk Management Plan (RMP) requirement

Boehringer Ingelheim China

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.